


L29 STRUCTURE UPLOADED

=> d

L29 HAS NO ANSWERS

L29 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l29 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 17:27:27 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 48 TO ITERATE

100.0% PROCESSED 48 ITERATIONS

18 ANSWERS

SEARCH TIME: 00.00.01

L30 18 SEA SSS FUL L29

L31 1 L30

=> d

L31 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:902181 CAPLUS

DN 141:366135

TI Preparation of (pyridinylalkylamino)benzeneacetamides and related compounds as protease inhibitors for use as anticoagulants

IN Kreutter, Kevin D.; Lee, Lily; Lu, Tianbao; Mohan, Venkatraman; Patel, Sharmila; Huang, Hui; Xu, Guozhang; Fitzgerald, Mark

PA 3-Dimensional Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI WO 2004091613 A2 20041028 WO 2004-US10034 20040401
 WO 2004091613 A3 20050127
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG
 US 2004254166 A1 20041216 US 2004-816544 20040401
 EP 1613319 A2 20060111 EP 2004-749611 20040401
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2006522809 T 20061005 JP 2006-509582 20040401
 PRAI US 2003-461421P P 20030410
 WO 2004-US10034 W 20040401
 OS MARPAT 141:366135



=> d ibib abs hitstr

L31 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:902181 CAPLUS
 DOCUMENT NUMBER: 141:366135
 TITLE: Preparation of (pyridinylalkylamino)benzeneacetamides
 and related compounds as protease inhibitors for use
 as anticoagulants
 INVENTOR(S): Kreutter, Kevin D.; Lee, Lily; Lu, Tianbao; Mohan,
 Venkatraman; Patel, Sharmila; Huang, Hui; Xu,
 Guozhang; Fitzgerald, Mark
 PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091613	A2	20041028	WO 2004-US10034	20040401
WO 2004091613	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004254166	A1	20041216	US 2004-816544	20040401
EP 1613319	A2	20060111	EP 2004-749611	20040401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522809	T	20061005	JP 2006-509582	20040401
PRIORITY APPLN. INFO.:			US 2003-461421P	P 20030410
			WO 2004-US10034	W 20040401

OTHER SOURCE(S) :
GI

MARPAT 141:366135



AB Title phenylacetamides I [wherein R1 = R2, R2(CH2)tC(R12)2, R2(OR12)C(CH2)p, (R2)2(OR12)C(CH2)p, R2C(R12)2(CH2)q, R2CH2C(R12)2(CH2)q, (R2)2CH(CH2)r, R2O(CH2)p, (R2)2CF(CH2)r, etc.; R2 = (un)substituted Ph, naphthyl, biphenyl, heterocyclyl, (bi)cycloalkyl; R3 = H, halo, OH; R4, R5 = independently H, halo, (halo)alkyl, alkenyl, alkynyl, hydroxy(alkyl), (halo)alkoxy, CN, NO2, carboxy, etc.; R6 = CN, acetylenyl; R11 = H, halo, alkyl; R12 = H, halo, CF3, (un)substituted alkyl; A = (un)substituted bicyclic heterocyclyl, heteroaryl; B = (un)substituted CH2(CH2)mCH2(CH2)nXNHC(=NH)NH2, (CH2)mCH2(CH2)n-aminopyridyl; (CH2)mCH2(CH2)nA; W = R1, R1SO2; X = O, NH, CH=N; Y = NH, O; m = 0-2; n = 0-2; p = 1-4; q = 0-2; r = 0-4; t = 0-3; and solvates, hydrates, or pharmaceutically acceptable salt thereof] were prepared as inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor

Xa. Compns. for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. I and their compns. are also useful as anticoagulants either embedded in or phys. linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents (no data). Addnl., the compds. can be detectably labeled and employed for in vivo imaging of thrombi (no data). Thus, saponification of [6-cyano-3-[[2,2-difluoro-2-(5-methylpyridin-2-yl)ethyl]amino]-2-fluorophenyl]acetic acid Et ester was saponified to the acid (no data) and condensed with N,N'-di(tert-butoxycarbonyl)-N''-(2-aminoethoxy)guanidine•HCl to give II. Compds. of the invention inhibited the ability of human thrombin to hydrolyze N-succinyl-Ala-Ala-Pro-Arg-p-nitroanilide with Ki values ranging from 0.0003 μM to 1.3 μM.


IT 780769-45-1P, N-[2-[[[N,N'-Bis(tert-butoxycarbonyl)amidino]amino]oxy]ethyl]-2-[3-[[2,2-difluoro-2-(5-methylpyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (pyridinylalkylamino)benzeneacetamides and related compds. as protease inhibitors)

RN 780769-45-1 CAPLUS

CN 5-Oxa-2,4,8-triazadec-2-enoic acid, 10-[6-cyano-3-[[2,2-difluoro-2-(5-

methyl-2-pyridinyl)ethyl]amino]-2-fluorophenyl]-3-[[[1,1-dimethylethoxy)carbonyl]amino]-9-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


Me

IT 780769-38-2P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(5-methylpyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide
 780769-60-0P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(6-methylpyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide
 780769-72-4P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(pyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide
 780769-86-0P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(5-chloropyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide
 780769-95-1P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(N-oxido-5-chloropyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide 780769-97-3P, N-[2-(Amidinoaminooxy)ethyl]-2-[6-cyano-3-[[2,2-difluoro-2-(1-oxidopyridin-2-yl)ethyl]amino]-2-fluorophenyl]acetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protease inhibitor; preparation of (pyridinylalkylamino)benzeneacetamides and related compds. as protease inhibitors)
 RN 780769-38-2 CAPLUS
 CN Benzeneacetamide, N-[2-[[[aminoiminomethyl]amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(5-methyl-2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 780769-60-0 CAPLUS
 CN Benzeneacetamide, N-[2-[[[aminoiminomethyl]amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(6-methyl-2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 780769-72-4 CAPLUS

CN Benzeneacetamide, N-[2-[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-6-cyano-3-
[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA INDEX
NAME)




RN 780769-86-0 CAPLUS

CN Benzeneacetamide, N-[2-[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-3-[[2-(5-
chloro-2-pyridinyl)-2,2-difluoroethyl]amino]-6-cyano-2-fluoro- (9CI) (CA
INDEX NAME)



RN 780769-95-1 CAPLUS


CN Benzeneacetamide, N-[2-[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-3-[[2-(5-
chloro-1-oxido-2-pyridinyl)-2,2-difluoroethyl]amino]-6-cyano-2-fluoro-
(9CI) (CA INDEX NAME)




RN 780769-97-3 CAPLUS

CN Benzeneacetamide, N-[2-[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-6-cyano-3-
[[2,2-difluoro-2-(1-oxido-2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA

INDEX NAME)




- IT 780769-46-2P 780769-58-6P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(4-methylpyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide 780769-59-7P 780769-61-1P 780769-62-2P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(3-methylpyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide 780769-63-3P 780769-77-9P, N-[2-(Amidinoaminooxy)ethyl]-2-[6-cyano-3-[[2,2-difluoro-2-(6-methyl-1-oxidopyridin-2-yl)ethyl]amino]-2-fluorophenyl]acetamide 780769-89-3P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(5-chloropyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide hydrochloride 780769-96-2P, N-[2-(Amidinoaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(N-oxide-5-chloropyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide hydrochloride 780769-98-4P 780770-03-8P, N-[2-(Amidino-N-methylaminooxy)ethyl]-2-[3-[[2,2-difluoro-2-(pyridin-2-yl)ethyl]amino]-6-cyano-2-fluorophenyl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protease inhibitor; preparation of (pyridinylalkylamino)benzeneacetamides and related compds. as protease inhibitors)
- RN 780769-46-2 CAPLUS
- CN Benzeneacetamide, N-[2-[[2-(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(5-methyl-2-pyridinyl)ethyl]amino]-2-fluoro-, hydrochloride (10:11) (9CI) (CA INDEX NAME)



●11/10 HCl

- RN 780769-58-6 CAPLUS
- CN Benzeneacetamide, N-[2-[[2-(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(4-methyl-2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 780769-59-7 CAPLUS

CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(4-methyl-2-pyridinyl)ethyl]amino]-2-fluoro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 780769-58-6


CMF C20 H22 F3 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 780769-61-1 CAPLUS

CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(6-methyl-2-pyridinyl)ethyl]amino]-2-fluoro-, hydrochloride (6:11) (9CI) (CA INDEX NAME)




RN 780769-62-2 CAPLUS
 CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-
 [[2,2-difluoro-2-(3-methyl-2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA
 INDEX NAME)



RN 780769-63-3 CAPLUS
 CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-
 [[2,2-difluoro-2-(3-methyl-2-pyridinyl)ethyl]amino]-2-fluoro-,
 trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 780769-62-2
 CMF C20 H22 F3 N7 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 780769-77-9 CAPLUS
 CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-
 [[2,2-difluoro-2-(6-methyl-1-oxido-2-pyridinyl)ethyl]amino]-2-fluoro-
 (9CI) (CA INDEX NAME)



RN 780769-89-3 CAPLUS


CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-3-[[2-(5-chloro-2-pyridinyl)-2,2-difluoroethyl]amino]-6-cyano-2-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 780769-96-2 CAPLUS


CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-3-[[2-(5-chloro-1-oxido-2-pyridinyl)-2,2-difluoroethyl]amino]-6-cyano-2-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 780769-98-4 CAPLUS


CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)amino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(1-oxido-2-pyridinyl)ethyl]amino]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 780770-03-8 CAPLUS

CN Benzeneacetamide, N-[2-[[[(aminoiminomethyl)methylamino]oxy]ethyl]-6-cyano-3-[[2,2-difluoro-2-(2-pyridinyl)ethyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)



=>